Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Recruiting 7Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Breast 5Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 5Metastatic Castration-Resistant Prostate Cancer 1Colorectal Neoplasms 1

Interventions

Specimen Handling 125pembrolizumab 123Magnetic Resonance Spectroscopy 108Carboplatin 89Cyclophosphamide 80Biopsy 69Cisplatin 67Paclitaxel 61Bevacizumab 56Gemcitabine 54Nivolumab 49fludarabine 48Dexamethasone 41Rituximab 39Pemetrexed 39Fluorouracil 39Radiotherapy 37Doxorubicin 37atezolizumab 36Docetaxel 36Leucovorin 35Oxaliplatin 32Capecitabine 32venetoclax 31Temozolomide 29Prednisone 29durvalumab 27Standard of Care 27Radiation 27Letrozole 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × inavolisib × 30 days × Clear all
NCT07287150 2026-06-04

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06790693 2026-06-03

INAVO123

Hoffmann-La Roche

Phase 3 Recruiting
450 enrolled
Breast

Breast Neoplasms

NCT05894239 2026-05-29

INAVO122

Hoffmann-La Roche

Phase 3 Recruiting
230 enrolled
Breast

Breast Neoplasms

NCT04929223 2026-05-26

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Hoffmann-La Roche

Phase 1 Recruiting
542 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07054190 2026-05-26

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms

NCT07347600 2026-05-18

reaINAVO

Hoffmann-La Roche

Recruiting
500 enrolled
Breast

Breast Neoplasms

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
80 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡